Folia Microbiologica

, Volume 59, Issue 2, pp 115–125

DNA persistence after treatment of Lyme borreliosis

  • D. Pícha
  • L. Moravcová
  • D. Vaňousová
  • J. Hercogová
  • Z. Blechová


One hundred twenty-four patients—53 with neuroborreliosis, 48 with erythema migrans, and 23 with Lyme arthritis—were tested in a prospective study for the presence of the DNA of Borrelia burgdorferi sensu lato in plasma, cerebrospinal fluid (CSF), urine, and synovial fluid by nested polymerase chain reaction (PCR). Specific DNA was detected using five amplification systems simultaneously: three targeted chromosomal genes encoding 16S rDNA, flagellin, and p66; and two plasmid sequences of OspA and OspC. Patients were examined clinically and by PCR before and after treatment and again after 3 and 6 months. Before treatment, the specific DNA was detected in 78 patients (62.9 %). Forty-one neuroborreliosis patients were DNA-positive (77.4 %), with CSF positivity in 26 patients, urine in 25, and plasma in 16. Twenty-six erythema migrans patients were DNA-positive (54.2 %), with plasma positivity in 18 cases and urine in 14. Eleven Lyme arthritis cases (47.8 %) were DNA positive (six in urine, five in plasma, and four in synovial fluid). The frequency of PCR positives was comparable in CSF and urine, and it was lower by approximately 50 % in plasma. Specific DNA was also found in a significant number of patients in later testing periods: 48 patients after treatment, 29 patients after 3 months, and 6 patients after 6 months. The prolonged PCR positivity was not explainable by persistent infection according to the clinical manifestations of the disease. Possible explanations of the problem are discussed.



Specific antibody index


Cerebrospinal fluid


Enzyme immunoassay


Erythema migrans


Immunosorbent electron microscopy


Lyme arthritis


Lyme disease




Polymerase chain reaction


Western blotting


  1. Aberer E, Bergmann AR, Derler A, Schmidt B (2007) Course of Borrelia burgdorferi DNA shedding in urine after treatment. Acta Derm Venereol 87:39–42PubMedCrossRefGoogle Scholar
  2. Bathe CH, Schwartz RA (2011) Lyme disease: part II. Management and prevention. J Am Acad Dermatol 64:639–653CrossRefGoogle Scholar
  3. Bergmann AR, Schmidt BL, Derler AM, Aberer E (2002) Importance of sample preparation for molecular diagnosis of Lyme borreliosis from urine. J Clin Microbiol 40:4581–4584PubMedCentralPubMedCrossRefGoogle Scholar
  4. Busson A, Reynders M, Van den Wijngaert S, Dahma H, Decolvenaer M, Vasseeuer L, Vandenberg O (2012) Evaluation of commercial screening tests and blot assays for the diagnosis of Lyme borreliosis. Diagn Microbiol Infect Dis 73:246–251PubMedCrossRefGoogle Scholar
  5. Cabello FC, Godfrey HP, Newman SA (2007) Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol 15:350–354PubMedCrossRefGoogle Scholar
  6. Dumler JS (2003) Molecular methods for ehrlichiosis and Lyme disease. Clin Lab Med 23:867–884PubMedCrossRefGoogle Scholar
  7. Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT (2012) Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One.:e29914. doi:10.1371/journal.pone.0029914
  8. Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Ad Hoc International Lyme Disease Group, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP Jr, Sood S, Weinstein A, Wong SJ, Zemel L (2007) A critical appraisal of “chronic Lyme disease”. N Engl J Med 357:1422–1430PubMedCrossRefGoogle Scholar
  9. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW (2008) Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 52:1728–1736PubMedCentralPubMedCrossRefGoogle Scholar
  10. Hulínská D, Votýpka J, Valešová M (1999) Borrelia garinii and Borrelia afzelii in patients with Lyme arthritis. Zentralbl Bakteriol 289:301–318PubMedCrossRefGoogle Scholar
  11. Iyer R, Mukherjee P, Wang K, Simons J, Wormser GP, Schwartz I (2012) Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability. J Clin Microbiol 51(3):857–62. doi:10.1128/JCM.02785-12 Google Scholar
  12. Kaiser R, Lücking CH (1993) Intrathecal synthesis of specific antibodies in neuroborreliosis, comparison of different ELISA techniques and calculation methods. J Neurol Sci 118:64–72PubMedCrossRefGoogle Scholar
  13. Lantos PM (2011) Chronic Lyme disease: the controversies and the science. Expert Rev Anti-Infect Ther 9:787–797PubMedCrossRefGoogle Scholar
  14. Lebech AM (2002) Polymerase chain reaction in diagnosis of Borrelia burgdorferi infection and studies on taxonomic classification. APMIS 110(Suppl 105):1–40Google Scholar
  15. Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I (2009) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17:8–16PubMedCrossRefGoogle Scholar
  16. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persinf DH, Steere AC (1994) Detection of Borrelia burgdorferi DNAby polymerase chain reaction in synovial fluid in Lyme arthritis. N Engl J Med 330:229–234PubMedCrossRefGoogle Scholar
  17. Nolte O (2012) Nucleid acid amplification based diagnostic of lyme (neuro-)borreliosis—lost in the jungle of methods, targets, and assays? Open Neurol J 6(Suppl 1-M):129–139PubMedCentralPubMedCrossRefGoogle Scholar
  18. Pícha D, Moravcová L, Ždárský E, Marešová V, Hulínský V (2005) PCR in Lyme neuroborreliosis: a prospective study. Acta Neurol Scand 112:287–292PubMedCrossRefGoogle Scholar
  19. Pícha D, Moravcová L, Holečková D, Ždárský E, Valešová M, Marešová V, Hercogová J, Vaňousová D (2008) Examination of specific DNA by PCR in patients with different forms of Lyme borreliosis. Int J Dermatol 47:1004–1010PubMedCrossRefGoogle Scholar
  20. Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A (1998) Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis 57:118–121PubMedCentralPubMedCrossRefGoogle Scholar
  21. Rauter C, Mueller M, Diterich I, Zeller S, Hassler D, Meergans T, Hartung T (2005) Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosis. Clin Diagn Lab Immunol 12:910–917PubMedCentralPubMedGoogle Scholar
  22. Stanek G, Wormser GP, Gray J, Strle F (2012) Lyme borreliosis. Lancet 379:461–473PubMedCrossRefGoogle Scholar
  23. Steere AC, Angelis SM (2006) Therapy for Lyme arthritis. Arthritis Rheum 54:3079–3086PubMedCrossRefGoogle Scholar
  24. Straubinger RK (2000) PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J Clin Microbiol 38:2191–2199PubMedCentralPubMedGoogle Scholar
  25. Stricker RB (2007) Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 45:149–157PubMedCrossRefGoogle Scholar
  26. Strle F, Cheng Y, Cimperman J, Maraspin V, Lotric-Furlan S, Nelson JA, Picken MM, Ruzic-Sabljic E, Picken RN (1995) Persistence of Borrelia burgdorferi sensulato in resolved erythema migrans lesions. Clin Infect Dis 21:380–389PubMedCrossRefGoogle Scholar
  27. Varde S, Wormser GP, Nowakowski J, Nadelman RB, Bittker S, Cooper D, Schwartz I (1999) Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro. Conn Med 63:589–591PubMedGoogle Scholar
  28. Wilske B, Fingerle V, Schulte-Spechtel U (2007) Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 49:13–21PubMedCrossRefGoogle Scholar
  29. Wormser GP, Shapiro ED (2009) Implications of gender in chronic Lyme disease. J Womens Health 18:831–834CrossRefGoogle Scholar
  30. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB (2006) The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis and Babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. IDSA Guidelines. Clin Infect Dis. 43: 1089–1134Google Scholar
  31. Wormser GP, Nadelman RB, Schwartz I (2012) The amber theory of Lyme arthritis: initial description and clinical implication. Clin Rheumatol 31:989–994PubMedCrossRefGoogle Scholar
  32. Yrjänäinen H, Hytönen J, Hartiala P, Oksi J, Viljanen MK (2010) Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS 118:665–673PubMedCrossRefGoogle Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i. 2013

Authors and Affiliations

  • D. Pícha
    • 1
  • L. Moravcová
    • 1
  • D. Vaňousová
    • 2
  • J. Hercogová
    • 2
  • Z. Blechová
    • 1
  1. 1.1st Clinic for Infectious Diseases, Hospital Na Bulovce, 2nd Medical SchoolCharles UniversityPragueCzech Republic
  2. 2.Clinic of Dermatology, Hospital Na Bulovce, 2nd Medical SchoolCharles UniversityPragueCzech Republic

Personalised recommendations